ライブラリ登録: Guest
Critical Reviews™ in Immunology

年間 6 号発行

ISSN 印刷: 1040-8401

ISSN オンライン: 2162-6472

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.3 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.6 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00079 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.24 SJR: 0.429 SNIP: 0.287 CiteScore™:: 2.7 H-Index: 81

Indexed in

A Unique Folate Hydrolase, Prostate-Specific Membrane Antigen (PSMA): A Target For Immunotherapy?

巻 21, 発行 1-3, 2001, 13 pages
DOI: 10.1615/CritRevImmunol.v21.i1-3.160
Get accessGet access

要約

Prostate-specific membrane antigen (PSMA) is a potential target in prostate cancer patients because it is very highly expressed and because it has been reported to be upregulated by androgen deprivation. This review discusses the historical background, biochemical characteristics, gene regulation, potential for targeting, tissue localization, and a novel T-body strategy.

によって引用された
  1. Slovin Susan F., Prostate-Specific Membrane Antigen Vaccines: Naked DNA and Protein Approaches, Clinical Prostate Cancer, 4, 2, 2005. Crossref

  2. Sazani Peter, Kole Ryszard, Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing, Journal of Clinical Investigation, 112, 4, 2003. Crossref

  3. Sazani Peter, Kole Ryszard, Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing, Journal of Clinical Investigation, 112, 4, 2003. Crossref

  4. O'Keefe Denise S., Bacich Dean J., Heston Warren D.W., Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene, The Prostate, 58, 2, 2004. Crossref

  5. Nedrow-Byers Jessie R., Moore Adam L., Ganguly Tanushree, Hopkins Mark R., Fulton Melody D., Benny Paul D., Berkman Clifford E., PSMA-targeted SPECT agents: Mode of binding effect on in vitro performance, The Prostate, 73, 4, 2013. Crossref

  6. Garbis Spiros D, Townsend Paul A, Proteomics of human prostate cancer biospecimens: the global, systems-wide perspective for Protein markers with potential clinical utility, Expert Review of Proteomics, 10, 4, 2013. Crossref

  7. Zhou Jia, Neale Joseph H., Pomper Martin G., Kozikowski Alan P., NAAG peptidase inhibitors and their potential for diagnosis and therapy, Nature Reviews Drug Discovery, 4, 12, 2005. Crossref

  8. Elsässer-Beile Ursula, Wolf Philipp, Gierschner Dorothee, Bühler Patrick, Schultze-Seemann Wolfgang, Wetterauer Ulrich, A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer, The Prostate, 66, 13, 2006. Crossref

  9. Ray Partha, Viles Kristi D., Soule Erin E., Woodruff Rebecca Smock, Application of Aptamers for Targeted Therapeutics, Archivum Immunologiae et Therapiae Experimentalis, 61, 4, 2013. Crossref

  10. Mesters Jeroen R, Barinka Cyril, Li Weixing, Tsukamoto Takashi, Majer Pavel, Slusher Barbara S, Konvalinka Jan, Hilgenfeld Rolf, Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer, The EMBO Journal, 25, 6, 2006. Crossref

  11. Wu Lisa Y., Liu Tiancheng, Grimm Amanda L., Davis William C., Berkman Clifford E., Flow cytometric detection of prostate tumor cells using chemoaffinity labels, The Prostate, 71, 1, 2011. Crossref

  12. Slovin Susan F, Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen, Expert Opinion on Therapeutic Targets, 9, 3, 2005. Crossref

  13. de Vrij Jeroen, Willemsen Ralph A., Lindholm Leif, Hoeben Rob C., Adenovirus-Derived Vectors for Prostate Cancer Gene Therapy, Human Gene Therapy, 21, 7, 2010. Crossref

  14. Liu Tiancheng, Wu Lisa Y., Kazak Marat, Berkman Clifford E., Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen, The Prostate, 68, 9, 2008. Crossref

  15. Liu Tiancheng, Wu Lisa Y., Choi Joseph K., Berkman Clifford E., In vitro targeted photodynamic therapy with a pyropheophorbide-a conjugated inhibitor of prostate-specific membrane antigen, The Prostate, 69, 6, 2009. Crossref

  16. Dharmasiri Udara, Balamurugan Subramanian, Adams André A., Okagbare Paul I., Obubuafo Annie, Soper Steven A., Highly efficient capture and enumeration of low abundance prostate cancer cells using prostate-specific membrane antigen aptamers immobilized to a polymeric microfluidic device, ELECTROPHORESIS, 30, 18, 2009. Crossref

  17. Wang Xinning, Yin Lihong, Rao Pravin, Stein Robert, Harsch Kelley M., Lee Zhenghong, Heston Warren D.W., Targeted treatment of prostate cancer, Journal of Cellular Biochemistry, 102, 3, 2007. Crossref

  18. Anderson Marc O., Wu Lisa Y., Santiago Nicholas M., Moser Jamie M., Rowley Jennifer A., Bolstad Erin S.D., Berkman Clifford E., Substrate specificity of prostate-specific membrane antigen, Bioorganic & Medicinal Chemistry, 15, 21, 2007. Crossref

  19. Mikolajczyk Stephen D., Song Yong, Wong James R., Matson Robert S., Rittenhouse Harry G., Are multiple markers the future of prostate cancer diagnostics?, Clinical Biochemistry, 37, 7, 2004. Crossref

  20. Ley Corinne R., Beattie Nathan R., Dannoon Shorouk, Regan Melanie, VanBrocklin Henry, Berkman Clifford E., Synthesis and evaluation of constrained phosphoramidate inhibitors of prostate-specific membrane antigen, Bioorganic & Medicinal Chemistry Letters, 25, 12, 2015. Crossref

  21. Wang Xinning, Tian Haibin, Lee Zhenghong, Heston Warren D. W., Structure-Activity Relationships of 2′,5′-Oligoadenylate Analogue Modifications of Prostate-Specific Membrane Antigen (PSMA) Antagonists, Nucleosides, Nucleotides and Nucleic Acids, 31, 5, 2012. Crossref

  22. Roach Mack, Alberini Jean-Louis, Pecking Alain Paul, Testori Alessandro, Verrecchia Francesco, Soteldo Javier, Ganswindt Ute, Joyal John L., Babich John W., Witte Russell S., Unger Evan, Gottlieb Ronald, Diagnostic and therapeutic imaging for cancer: Therapeutic considerations and future directions, Journal of Surgical Oncology, 103, 6, 2011. Crossref

  23. Sammouda Rachid Said, Wang Xinning, Basilion James P., Hopfield Neural Network for the segmentation of Near Infrared Fluorescent images for diagnosing prostate cancer, 2015 6th International Conference on Information and Communication Systems (ICICS), 2015. Crossref

  24. Nedrow-Byers Jessie R., Jabbes Mohamed, Jewett Cayla, Ganguly Tanushree, He Haiyang, Liu Tiancheng, Benny Paul, Bryan Jeffrey N., Berkman Clifford E., A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent, The Prostate, 72, 8, 2012. Crossref

  25. Wu Lisa Y., Anderson Marc O., Toriyabe Yoko, Maung Jack, Campbell Tammy Y., Tajon Cheryl, Kazak Marat, Moser Jamie, Berkman Clifford E., The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen, Bioorganic & Medicinal Chemistry, 15, 23, 2007. Crossref

  26. Chen Ying, Dhara Surajit, Banerjee Sangeeta Ray, Byun Youngjoo, Pullambhatla Mrudula, Mease Ronnie C., Pomper Martin G., A low molecular weight PSMA-based fluorescent imaging agent for cancer, Biochemical and Biophysical Research Communications, 390, 3, 2009. Crossref

  27. Dermime Said, Gilham David E, Shaw David M, Davidson Emma J, Meziane El-Kahina, Armstrong Anne, Hawkins Robert E, Stern Peter L, Vaccine and antibody-directed T cell tumour immunotherapy, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1704, 1, 2004. Crossref

  28. Wu Lisa Y., Do Jacinda C., Kazak Marat, Page Helen, Toriyabe Yoko, Anderson Marc O., Berkman Clifford E., Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen, Bioorganic & Medicinal Chemistry Letters, 18, 1, 2008. Crossref

  29. Wone David W.G., Rowley Jennifer A., Garofalo Albert W., Berkman Clifford E., Optimizing phenylethylphosphonamidates for the inhibition of prostate-specific membrane antigen, Bioorganic & Medicinal Chemistry, 14, 1, 2006. Crossref

  30. Sammouda Rachid, Aboalsamh Hatim, Saeed Fahman, Comparison between K mean and fuzzy C-mean methods for segmentation of near infrared fluorescent image for diagnosing prostate cancer, International Conference on Computer Vision and Image Analysis Applications, 2015. Crossref

  31. Zhou Jiehua, Rossi John, Aptamers as targeted therapeutics: current potential and challenges, Nature Reviews Drug Discovery, 16, 3, 2017. Crossref

  32. Ray Partha, White Rebekah R., Aptamers for Targeted Drug Delivery, Pharmaceuticals, 3, 6, 2010. Crossref

  33. Bouchelouche Kirsten, Choyke Peter L., Prostate-specific membrane antigen positron emission tomography in prostate cancer, Current Opinion in Oncology, 28, 3, 2016. Crossref

  34. Lee Hak Jong, Yoon Young Il, Bae Yun Jung, Theragnostic ultrasound using microbubbles in the treatment of prostate cancer, Ultrasonography, 35, 4, 2016. Crossref

  35. Hohberg Melanie, Eschner Wolfgang, Schmidt Matthias, Dietlein Markus, Kobe Carsten, Fischer Thomas, Drzezga Alexander, Wild Markus, Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [177Lu]DKFZ-PSMA-617, Molecular Imaging and Biology, 18, 3, 2016. Crossref

  36. Yin Lihong, Rao Pravin, Elson Paul, Wang Jianghua, Ittmann Michael, Heston Warren D. W., Bauer Joseph Alan, Role of TMPRSS2-ERG Gene Fusion in Negative Regulation of PSMA Expression, PLoS ONE, 6, 6, 2011. Crossref

  37. Shah Syed Qaiser, Gul-e-Raana , Uddin Ghias, Imaging prostate cancer (PCa) with [99m Tc(CO)3 ]finasteride dithiocarbamate, Journal of Labelled Compounds and Radiopharmaceuticals, 61, 7, 2018. Crossref

  38. Psimadas Dimitrios, Valotassiou Varvara, Alexiou Sotiria, Tsougos Ioannis, Georgoulias Panagiotis, Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA, Cancer Investigation, 36, 2, 2018. Crossref

  39. Kularatne Sumith A., Zhou Zhigang, Yang Jun, Post Carol B., Low Philip S., Design, Synthesis, and Preclinical Evaluation of Prostate-Specific Membrane Antigen Targeted 99mTc-Radioimaging Agents, Molecular Pharmaceutics, 6, 3, 2009. Crossref

  40. Gardner Thomas A., Jiménez Juan Antonio, Chung Leland W. K., Kao Chinghai, Antimetastatic Gene Therapy, in Cancer Gene Therapy, 2005. Crossref

  41. Sengupta Sagnik, Asha Krishnan Mena, Chattopadhyay Sudeshna, Chelvam Venkatesh, Comparison of prostate‐specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer, CANCER REPORTS, 2019. Crossref

  42. Kularatne Sumith A., Wang Kevin, Santhapuram Hari-Krishna R., Low Philip S., Prostate-Specific Membrane Antigen Targeted Imaging and Therapy of Prostate Cancer Using a PSMA Inhibitor as a Homing Ligand, Molecular Pharmaceutics, 6, 3, 2009. Crossref

  43. Zhou Jiehua, Rossi John J., The Potential and Current Progress of Internalizing Molecules in Targeted Drug Delivery, in Intracellular Delivery, 5, 2011. Crossref

  44. Potemkin Roman, Strauch Brigitte, Kuwert Torsten, Prante Olaf, Maschauer Simone, Development of 18F-Fluoroglycosylated PSMA-Ligands with Improved Renal Clearance Behavior, Molecular Pharmaceutics, 17, 3, 2020. Crossref

  45. Violet John, Jackson Price, Ferdinandus Justin, Sandhu Shahneen, Akhurst Tim, Iravani Amir, Kong Grace, Kumar Aravind Ravi, Thang Sue Ping, Eu Peter, Scalzo Mark, Murphy Declan, Williams Scott, Hicks Rodney J., Hofman Michael S., Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes, Journal of Nuclear Medicine, 60, 4, 2019. Crossref

  46. Graham Keith, Lesche Ralf, Gromov Alexey V., Böhnke Niels, Schäfer Martina, Hassfeld Jorma, Dinkelborg Ludger, Kettschau Georg, Radiofluorinated Derivatives of 2-(Phosphonomethyl)pentanedioic Acid as Inhibitors of Prostate Specific Membrane Antigen (PSMA) for the Imaging of Prostate Cancer, Journal of Medicinal Chemistry, 55, 22, 2012. Crossref

  47. Olatunji Feyisola P., Savoy Emily A., Panteah Mylan, Mesbahi Nooshin, Abbasi Armina, Talley Cresencia M., Lovingier Christine L., Caromile Leslie A., Berkman Clifford E., Prostate-Specific Membrane Antigen-Targeted Turn-on Probe for Imaging Cargo Release in Prostate Cancer Cells, Bioconjugate Chemistry, 32, 11, 2021. Crossref

  48. Wang Xinning, Luo Dong, Basilion James P., Photodynamic Therapy: Targeting Cancer Biomarkers for the Treatment of Cancers, Cancers, 13, 12, 2021. Crossref

  49. Dannoon Shorouk, Ganguly Tanushree, Cahaya Hendry, Geruntho Jonathan J., Galliher Matthew S., Beyer Sophia K., Choy Cindy J., Hopkins Mark R., Regan Melanie, Blecha Joseph E., Skultetyova Lubica, Drake Christopher R., Jivan Salma, Barinka Cyril, Jones Ella F., Berkman Clifford E., VanBrocklin Henry F., Structure–Activity Relationship of 18F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer, Journal of Medicinal Chemistry, 59, 12, 2016. Crossref

  50. Maresca K. P., Hillier S. M., Femia F. J., Keith D., Barone C., Joyal J. L., Zimmerman C. N., Kozikowski A. P., Barrett J. A., Eckelman W. C., Babich J. W., A Series of Halogenated Heterodimeric Inhibitors of Prostate Specific Membrane Antigen (PSMA) as Radiolabeled Probes for Targeting Prostate Cancer, Journal of Medicinal Chemistry, 52, 2, 2009. Crossref

  51. McEnaney Patrick J., Fitzgerald Kelly J., Zhang Andrew X., Douglass Eugene F., Shan Weifang, Balog Aaron, Kolesnikova Mariya D., Spiegel David A., Chemically Synthesized Molecules with the Targeting and Effector Functions of Antibodies, Journal of the American Chemical Society, 136, 52, 2014. Crossref

  52. Nimjee Shahid M., Rusconi Christopher P., Sullenger Bruce A., Aptamers: An Emerging Class of Therapeutics, Annual Review of Medicine, 56, 1, 2005. Crossref

  53. Maung Jack, Mallari Jeremy P., Girtsman Teri A., Wu Lisa Y., Rowley Jennifer A., Santiago Nicholas M., Brunelle Alan N., Berkman Clifford E., Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates, Bioorganic & Medicinal Chemistry, 12, 18, 2004. Crossref

  54. Banerjee Sangeeta R., Foss Catherine A., Castanares Mark, Mease Ronnie C., Byun Youngjoo, Fox James J., Hilton John, Lupold Shawn E., Kozikowski Alan P., Pomper Martin G., Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA), Journal of Medicinal Chemistry, 51, 15, 2008. Crossref

  55. Henry Michael D., Wen Shenghua, Silva Matthew D., Chandra Sudeep, Milton Mark, Worland Peter J., A Prostate-Specific Membrane Antigen-Targeted Monoclonal Antibody–Chemotherapeutic Conjugate Designed for the Treatment of Prostate Cancer, Cancer Research, 64, 21, 2004. Crossref

  56. Foss Catherine A., Mease Ronnie C., Fan Hong, Wang Yuchuan, Ravert Hayden T., Dannals Robert F., Olszewski Rafal T., Heston Warren D., Kozikowski Alan P., Pomper Martin G., Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen: In vivo Imaging in Experimental Models of Prostate Cancer, Clinical Cancer Research, 11, 11, 2005. Crossref

  57. Zhou Shuoming, Liu Tiantian, Zhu Ziqiang, Zhang Lin, Qian Subo, Fu Hongliang, Cao Qifeng, Kang Jian, 18F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer, Frontiers in Oncology, 12, 2022. Crossref

  58. Wang Xinning, Huang Steve S., Heston Warren D.W., Guo Hong, Wang Bing-Cheng, Basilion James P., Development of Targeted Near-Infrared Imaging Agents for Prostate Cancer, Molecular Cancer Therapeutics, 13, 11, 2014. Crossref

  59. Kaewput Chalermrat, Vinjamuri Sobhan, Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends, Journal of Clinical Medicine, 11, 10, 2022. Crossref

  60. Mease Ronnie C., Dusich Crystal L., Foss Catherine A., Ravert Hayden T., Dannals Robert F., Seidel Jurgen, Prideaux Andrew, Fox James J., Sgouros George, Kozikowski Alan P., Pomper Martin G., N-[N-[(S)-1,3-Dicarboxypropyl]Carbamoyl]-4-[18F]Fluorobenzyl-l-Cysteine, [18F]DCFBC: A New Imaging Probe for Prostate Cancer, Clinical Cancer Research, 14, 10, 2008. Crossref

  61. Hayes Gregory M, Dougherty Shona T, Davis Peter D, Dougherty Graeme J, Molecular mechanisms regulating the tumor-targeting potential of splice-activated gene expression, Cancer Gene Therapy, 11, 12, 2004. Crossref

  62. Xiao Zeyu, Frieder Jillian, Teply Benjamin A., Farokhzad Omid C., Aptamer Conjugates: Emerging Delivery Platforms for Targeted Cancer Therapy, in Drug Delivery in Oncology, 2011. Crossref

  63. Exner Agata A., Kolios Michael C., Bursting microbubbles: How nanobubble contrast agents can enable the future of medical ultrasound molecular imaging and image-guided therapy, Current Opinion in Colloid & Interface Science, 54, 2021. Crossref

  64. Medin Jeffrey A, Liang Sheng-Ben, Hou Jeannie Whit-Shan, Kelley Leslie S, Peace David J, Fowler Daniel H, Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo, Cancer Gene Therapy, 12, 6, 2005. Crossref

  65. Sergeeva Olga, Zhang Yifan, Julian Willian, Sasikumar Arun, Awadallah Amad, Kenyon Jonathan, Shi Wuxian, Sergeev Maxim, Huang Steve, Sexton Sandra, Iyer Renuka, Xin Wei, Avril Norbert, Chan Ernest Ricky, Lee Zhenghong, Imaging of Tumor-Associated Vascular Prostate-Specific Membrane Antigen in Woodchuck Model of Hepatocellular Carcinoma, Gastro Hep Advances, 1, 4, 2022. Crossref

近刊の記事

Identification of a novel five-gene prognostic model for laryngeal cancer associated with mitophagy using integrated bioinformatics analysis and experimental verification Dong Song, Lun Dong, Mei Wang, Xiaoping Gao Function of steroid receptor coactivators (SRCs) in T cells and cancers: Implications for cancer immunotherapy Wencan Zhang, Xu Cao, Hongmin Wu, Xiancai Zhong, Yun Shi, Zuoming Sun Electroacupuncture Alleviates Ischemic Stroke by Activating the mTOR/SREBP1 Pathway Jiawang Lang, Jianchang Luo, Luodan Wang, Wenbin Xu, Jie Jia, Zhipeng Zhao, Boxu Lang KIAA1429 induces the m6A modification of LINC01106 to enhance the malignancy of lung adenocarcinoma cell via JAK/STAT3 pathway Di Xu, Ziming Wang, Fajiu Li Effect of p-estrogen receptor at serine on its function and breast growth Yuan Liang, Junhui Qin, Tiancheng Ma, Tong Yang, Zhenyu Ke, Ruian Wang Mechanistic Insights into Tanshinone IIA in the Amelioration of Post-Thyroidectomy Hypoparathyroidism Xiaoyu Qian, Lin Li, Liang Chen, Chao Shen, Jian Tang MiRNA let-7d-5p alleviates inflammatory responses by targeting Map3k1 and inactivating ERK/p38 MAPK signaling in microglia Fan Fang, Cheng Chen Role of Natural Killer Cells as Cell-Based Immunotherapy in Oral Tumor Eradication and Differentiation Both In Vivo and In Vitro Kawaljit Kaur, Anahid Jewett The Current and Future States of Natural Killer Cell-Based Immunotherapy in Hepatocellular Carcinoma Tu Nguyen, Po-Chun Chen, Janet Pham, Kawaljit Kaur, Steven Raman, Anahid Jewett, Jason Chiang Phillygenin alleviated arthritis through the inhibition of NLRP3 inflammasome and Ferroptosis by AMPK Jianghui Wang, Shufang Ni, Kai Zheng, Yan Zhao, peihong zhang, Hong Chang The value of systemic immune-inflammation index and T cell subsets in the severity and prognosis of sepsis Hao Zhou Efficacy and Nuances of Precision Molecular Engineering for Hodgkin's Disease to a Gene Therapeutic Approach Muhammad Imran Qadir, Bilal Ahmed, Nadir Hussain Serum interleukin 6 and ferritin levels are the independent risk factors for pneumonia in elderly patients Hao Yuan, Jing Tian, Lu Wen Exploration of diagnostic markers associated with inflammation in chronic kidney disease (CKD) based on WGCNA and machine learning Qianjia Wu, Yang Yang, Chongze Lin Clinical significance of serum CTRP3 level in the prediction of cardiac dysfunction and intestinal mucosal barrier dysfunction in patients with severe acute pancreatitis Qiang Shao, Lin Sun The protective effect and mechanism of mild hypothermia on pig lung injury after cardiopulmonary resuscitation Jinlin Ren, Fangfang Zhu, Dongdong Sang, Mulin Cong, Shujuan Jiang Exploring mechanism of Zilongjin in treating lung adenocarcinoma based on network pharmacology combined with experimental verification Kang Zhang, Xiaoqun Chen Gastric Cancer Immune Subtypes and Prognostic Modeling: Insights from Aging-Related Genes Analysis Jian Shen, Minzhe Li Effects of different doses of dexmedetomidine on the prevention of postoperative sleep disturbance and serum neurotransmitter level in patients under general anesthesia Huifei Lu, Fei He, Ying Huang, Zhongliang Wei Identification of key ubiquitination-related genes and their associated with immune infiltration in osteoarthritis based on mRNA-miRNA network Dalu Yuan, Hailiang Shen, Lina Bai, Menglin Li, Qiujie Ye Diagnostic and Prognostic value of peripheral neutrophil CD64 index in elderly patients with community-acquired pneumonia Yan Li, Jing Zhang, Suhang Wang, Jie Cao Identification of Metabolism-Related Prognostic Biomarkers and Immune Features of Head and Neck Squamous Cell Carcinoma Rongjin Zhou, Junguo Wang Downregulation of miR-503-5p promotes the development of pancreatic cancer via targeting cyclin E2 Fei Li, Ying-pei Ling, Pan Wang, Shi-cheng Gu, Hao Jiang, Jie Zhu
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集 価格及び購読のポリシー Begell House 連絡先 Language English 中文 Русский Português German French Spain